ZERO WINTERDEAL 2025: Bis zu 300 € Prämie + Gratis-Aktie + finanzen.net MSCI World-ETF – Jetzt informieren!

Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

20.10.25 09:34 Uhr

Werte in diesem Artikel
Aktien

49,80 EUR 0,00 EUR 0,00%

LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics " or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD:  December 27, 2023 to May 6, 2025

DEADLINE: November 17, 2025

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Cytokinetics touted the expected FDA approval of aficamten to investors, stating that it expected approval in the second half of 2025. The Company failed to submit a Risk Evaluation and Mitigation Strategy ("REMS"), which could delay the FDA's approval process. The Company later admitted it did not submit a REMS despite multiple pre-NDA meetings with the FDA on the subject of risk mitigation. Based on these facts, Cytokinetics' public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate .

NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.

WHY DJS LAW GROUP?  DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

 Eastchester, NY 10709

Phone: 914-206-9742

Email: David@djslawllp.com

Cision View original content:https://www.prnewswire.com/news-releases/cytokinetics-incorporated-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--cytk-302588545.html

SOURCE DJS Law Group LLP

In eigener Sache

Übrigens: Cytokinetics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Cytokinetics

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Cytokinetics

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Cytokinetics Inc

Wer­bung

Analysen zu Cytokinetics Inc

DatumRatingAnalyst
21.09.2018Cytokinetics OverweightCantor Fitzgerald
22.11.2017Cytokinetics BuyNeedham & Company, LLC
21.11.2017Cytokinetics BuyH.C. Wainwright & Co.
08.03.2017Cytokinetics BuyRodman & Renshaw, LLC
06.02.2017Cytokinetics Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
21.09.2018Cytokinetics OverweightCantor Fitzgerald
22.11.2017Cytokinetics BuyNeedham & Company, LLC
21.11.2017Cytokinetics BuyH.C. Wainwright & Co.
08.03.2017Cytokinetics BuyRodman & Renshaw, LLC
06.02.2017Cytokinetics Strong BuyNeedham & Company, LLC
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Cytokinetics Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen